Drug intelligence / Profile preview

EYP-2301

Development stage: Phase 2
Lead developer: EyePoint Pharmaceuticals
Modality: Small Molecules
Administration: Intraocular, Intravitreal

Overview

EYP-2301 is a proprietary formulation of razuprotafib, a small molecule TIE-2 (TEK receptor tyrosine kinase) agonist, delivered using EyePoint Pharmaceuticals’ sustained-release Durasert E™ technology. The drug is being developed as a novel mechanism of action therapy for serious retinal diseases, with the aim to improve outcomes by activating the TIE-2 pathway and stabilizing retinal vasculature. Its primary indication under investigation is wet age-related macular degeneration (wet AMD). As of December 2023, it remains in preclinical development[1][2][3][4][5].

Other names: razuprotafib in Durasert E

Targets

TEK (Tie2)

Beyond the preview

Go deeper on EYP-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EYP-2301.

Explore the full profile